Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) has announced a new phase I/II clinical trial of Apoptone (HE3235) for late stage prostate cancer. Howard Scher, M.D., Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center said "The preclinical data generated to date suggest that Apoptone may offer a unique therapeutic approach to late-stage prostate cancer where [...]
Amgen just completed, with positive results, a three-year Phase 3 placebo-controlled trial which evaluated denosumab for the treatment of bone loss (reduction of bone mineral density –BMD) in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. One of the more common and significant side effects of ADT is loss of BMD. This loss [...]
According to a study published April 16, 2008, regular exercise is the best way to manage cancer-related fatigue! Fatigue is a common problem for men with prostate cancer. It is also a common side effect of all the available prostate cancer treatments, both primary and secondary treatments. The most common advice we receive for coping [...]
It is my understanding that almost 90% of men who start hormone therapy initially respond to the drugs with their PSA falling significantly. However, there are many costs associated with ADT, many of which I have already discussed in this blog. The hot flashes, bone loss, weight gain, decreased libido and erectile dysfunction are often [...]
The last few days have seen a lot of commotion and celebrating in the prostate cancer world. There have been multiple news stories of an experimental prostate cancer drug, abiraterone, that has been reported to dramatically shrink prostate cancer tumors and extend survival in 70 to 80 percent of men with aggressive prostate cancer. Abiraterone [...]